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Abstract
Background: The metabolism of cancer cells is often reprogrammed by dysregulation of metabolic enzymes.
Transketolase-like 1 (TKTL1) is a homodimeric transketolase linking the pentose-phosphate pathway with the
glycolytic pathway. It is generally silenced at a transcriptional level in somatic tissues. However, in human cancers
its expression is associated with the acquisition of a glycolytic phenotype (the Warburg effect) by cancer cells that
contributes to the progression of malignant tumors. In melanoma, defective promoter methylation results in the
expression of genes and their products that can affect the tumor cell’s phenotype including the modification of
immune and functional characteristics. The present study evaluates the role of TKTL1 as a mediator of disease
progression in melanoma associated with a defective methylation phenotype.
Methods: The expression of TKTL1 in metastatic melanoma tumors and cell lines was analysed by qRT-PCR and
immunohistochemistry. The promoter methylation status of TKTL1 in melanoma cells was evaluated by quantitative
methylation specific PCR. Using qRT-PCR, the effect of a DNA demethylating agent 5-aza-2’-deoxycytidine (5aza) on
the expression of TKTL1 was examined. Biochemical and molecular analyses such as glucose consumption, lactate
production, invasion, proliferation and cell cycle progression together with ectopic expression and siRNA mediated
knockdown were used to investigate the role of TKTL1 in melanoma cells.
Results: Expression of TKTL1 was highly restricted in normal adult tissues and was overexpressed in a subset of
metastatic melanoma tumors and derived cell lines. The TKTL1 promoter was activated by hypomethylation and
treatment with 5aza induced TKTL1 expression in melanoma cells. Augmented expression of TKTL1 in melanoma
cells was associated with a glycolytic phenotype. Loss and gain of function studies revealed that TKTL1 contributed
to enhanced invasion of melanoma cells.
Conclusions: Our data provide evidence for an important role of TKTL1 in aerobic glycolysis and tumor promotion
in melanoma that may result from defective promoter methylation. This epigenetic change may enable the natural
selection of tumor cells with a metabolic phenotype and thereby provide a potential therapeutic target for a subset
of melanoma tumors with elevated TKTL1 expression.
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Background
Melanoma is a cancer derived from neuroectoderm that
is often fatal once it has metastasised [1, 2]. Current
treatment approaches include the molecular targeting of
oncogenic gene products and immune-based therapies,
both of which induce significant responses in many pa-
tients with advanced disease [3, 4]. Despite this, many
patients develop therapy resistance or do not respond to
treatment [5–7]. Since alterations in cellular metabolism
may contribute to the malignant phenotype, targeting
the metabolic circuitry of melanoma cells may offer a
promising additional therapeutic strategy [8, 9].
The reprogramming of cellular metabolism is one of
the hallmarks of cancer [10]. Whereas normal cells dir-
ect glucose to mitochondrial oxidative phosphorylation
to generate ATP when oxygen is abundant, cancer cells
generally exhibit greater glucose uptake and lactate secre-
tion, regardless of oxygen availability. This phenomenon is
termed “aerobic glycolysis” or the “Warburg effect”
[10–12]. This can benefit cancer cells by facilitating in-
creased proliferation, enhanced invasion and resistance to
apoptosis, which in turn promote tumor progression and
metastasis [13]. These observations have raised the possi-
bility that targeting metabolic pathways that the cancer
cell depends upon may be a useful therapeutic strategy.
Metabolic profiling of melanoma cells has revealed their
dependence upon the Warburg effect as the major source
of energy [14]. Moreover, this phenomenon is the basis for
18FDG-PET (Fluorodeoxy glucose positron emission tom-
ography) to image the metabolic activity of cancer in
patients [15].
Transketolases are essential and rate-limiting enzymes
in the non-oxidative part of the pentose-phosphate path-
way [16, 17]. An augmented pentose-phosphate pathway
in some tumors enables oxygen-independent glucose
conversion to ribose for nucleic acid synthesis, glucose
degradation to lactate, and regeneration of redox equiva-
lents [18]. The transketolase family includes Transketo-
lase (TKT), and two Transketolase-like proteins (TKTL1
and TKTL2) [19]. Among them, TKTL1 is the isoform
specifically upregulated in different human cancers such
as head and neck, lung, breast, stomach, colon, nephro-
blastoma and endometrial cancer [20–26]. Its overexpres-
sion predicts poor patient survival, tumor recurrence and
resistance to chemo and radiation therapy in many can-
cers [23, 27, 28]. TKTL1 expression was demonstrated in
invasive tumors which correlated with increased metasta-
sis [29]. Some of the tumor types expressing TKTL1 have
responded to the transketolase inhibitor Oxythiamine that
effectively blocked cell proliferation [30, 31]. TKTL1 has
recently been used as a biomarker in a blood test based on
the epitope detection in monocytes (EDIM) technology
allowing for the non-invasive detection of neoplasia and
tumor recurrence [32]. Although TKTL1 expression in
conjunctival melanoma tumors has been reported, the
mechanism by which expression becomes unregulated
and the functional consequences of aberrant TKTL1 ex-
pression in melanoma remains unclear and these warrant
further investigation [33].
Methylation defects are commonly observed in melan-
oma and this can result in the expression of gene prod-
ucts that are otherwise silenced at a transcriptional level
in somatic tissues. This can profoundly affect the pheno-
type of the cancer cell. Among these re-expressed pro-
tein are the Cancer Testis or Cancer Germ-line family of
antigens (CTAg); so called because they are often im-
munogenic and can mediate the immune rejection of
cancer [34]. They are associated with disease progression
and may be associated with poorer clinical outcomes in
melanoma and other cancers [35, 36]. Many of these are
coded on the X chromosome and their function is poorly
understood although the association with stem-like char-
acteristics has been reported [37]. Given that TKTL1 is
also an X chromosome coded molecule (Xq28) that, like
the CTAg, is generally repressed in somatic tissues, we
sought to determine if DNA hypomethylation also in-
duced aberrant expression of TKTL1 in melanoma and to
assess its role in promoting the Warburg effect in melan-
oma cells.
We detected increased expression of TKTL1 in a sub-
set of metastatic melanoma tumors and cell lines and
found TKTL1 expression in melanoma tumors was asso-
ciated with promoter hypomethylation. We demon-
strated that the TKTL1 promoter could be activated by
treatment with 5-aza-2’-deoxycytidine (5aza) thereby in-
ducing TKTL1 expression in melanoma cells. Elevated
TKTL1 expression enhanced the Warburg effect by ac-
celerating glucose utilisation and lactate production and
TKTL1 loss and gain of function studies revealed that
TKTL1 enhanced invasion in melanoma cells. Taken to-
gether, our data suggests that a subset of melanomas
with defective methylation rely on TKTL1-dependent
aerobic glycolysis and have enhanced tumorigenesis.
These may be amenable to inhibition of the Warburg ef-
fect by therapies that target TKTL1.
Results
A subset of metastatic melanoma tumors and cell lines
express TKTL1
We quantified TKTL1 transcripts by qRT-PCR in a panel
of normal human tissues and metastatic melanoma tu-
mors. Figure 1a shows that high expression of TKTL1
mRNA was detected in testis but no other normal hu-
man tissues tested including skin and melanocytes. 15 of
38 (40 %) melanoma tumors assessed expressed TKTL1
to varying degrees. We examined TKTL1 by immuno-
histochemistry using a tissue microarray (TMA) com-
prising 81 tumors from patients with stage III and IV
































































































































































Fig. 1 (See legend on next page.)
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metastatic melanoma. Four representative tumors with
high and diffuse intensity staining of tumor cells for
TKTL1 are depicted in Fig. 1b. TKTL1 in tumors varied
from homogenous to heterogeneous expression with
clusters of TKTL1 positive cells interspersed with TKTL1
negative cells. TKTL1 expression in testis tissue was used
as positive control and anti-IgG antibody was used as
negative control (Fig. 1b). 31 of 81 (38 %) of metastatic
melanoma tumors were scored positive for TKTL1 ex-
pression (Fig. 1c). High magnification image shows that
TKTL1 localization is predominantly cytosolic and mem-
brane staining is also seen in some melanoma tumor cells.
Nuclear staining in some tumors is Melanin (brown) and
not TKTL1 (red) (Additional file 1: Figure S1A). We ex-
tended our studies to a clinical outcome dataset that sub-
divided 57 stage IV melanoma samples into high-risk or
low-risk melanoma groups based on transcriptome profil-
ing (GSE22153) [38]. We found that tumors expressing
high TKTL1 levels were statistically significantly associated
with the high-risk group (log-rank p value 0.0277), risk be-
ing reduced survival and risk of relapse.
In a panel of 53 metastatic melanoma cell lines TKTL1
mRNA was detectable in 11 of 53 lines (20 %) by qRT-
PCR (Additional file 1: Figure S1B). We selected two cell
lines for further functional studies; LM-MEL-59, which
showed the highest level of TKTL1 mRNA expression and
LM-MEL-44 which lacked TKTL1 expression (Fig. 2a).
Immuno-staining confirmed the expression of TKTL1 in
LM-MEL-59 and its absence in LM-MEL-44 (Fig. 2b).
Both of these cell lines lack activating mutations in the
BRAF protein kinase. High magnification image confirms
cytosolic TKTL1 localization (Additional file 1: Figure S1C).
Promoter hypomethylation of the TKTL1 gene is
responsible for its activation in melanoma
Expression of TKTL1 has been reported to be controlled
by methylation and demethylation of TKTL1 has been
previously reported in lung and head and neck cancers
[24, 39]. However, little is known about the methylation
status of TKTL1 in melanoma. To investigate promoter
cytosine-(phosphate)-guanine (CpG) dinucleotide DNA
methylation, we quantified the level of TKTL1 promoter
methylation using bisulfite modification and MS-qPCR.
Melanocytes were found to be hypermethylated which
correlated with the lack of TKTL1 expression in those
cells (Fig. 2c), while metastatic melanoma cell lines tested
showed reduced methylation levels when compared to
melanocytes. LM-MEL-44 cell line with no TKTL1 expres-
sion showed hypermethylation of the TKTL1 promoter
whereas a lesser degree of TKTL1 promoter methylation
was detected in LM-MEL-59 with high TKTL1 mRNA ex-
pression. Promoter hypermethylation of TKTL1 could be
reversed by a DNA demethylating agent 5-aza-2′-deoxy-
cytidine (5aza) in LM-MEL-44 resulting in the expression
of TKTL1 in treated LM-MEL-44 cells in contrast to
DMSO treated cells (Fig. 2d).
We extended our studies to a publically available clin-
ical melanoma patient dataset to determine whether de-
regulation of TKTL1 expression was linked to DNA
hypomethylation. Using MethPrimer (www.urogene.org/
cgi-bin/methprimer/methprimer.cgi), a CpG island pre-
diction program, we identified two CpG sites in the
TKTL1 promoter that were highly prone to methylation
(data not shown). The primers we designed for MS-qPCR
spanned these two CpG sites; cg09892236 (−100 bp of
transcription start site (TSS)) and cg23106779 (−250 bp of
TSS). We used an in silico approach to assess the methyla-
tion status of the promoter region on the TKTL1 gene in
385 metastatic melanoma tissues from the Skin Cutaneous
Melanoma (SKCM) dataset of The Cancer Genome Atlas
(TCGA) database (www.cbioportal.org) [40, 41] and esti-
mated its association with TKTL1 mRNA expression. We
first evaluated DNA methylation of the two CpG sites
using the Illumina Infinium Human Methylation 450 k
BeadChip array (450 k array). Methylation of the two CpG
sites were statistically associated with each other with the
melanoma dataset (correlation = 0.68, p-value = 2.2e-16).
We next examined the exon and gene expression pattern
of TKTL1 in these patient samples in the Illumina Hiseq
RNA-Seq Platforms. Spearman correlation coefficients
were calculated to test the correlations between DNA
methylation and gene expression of TKTL1. We found
that methylation status at both the CpG sites was statisti-
cally inversely correlated with TKTL1 gene expression in
melanoma samples (Table 1 and Additional file 2: Figure
S2A&B). Melanoma samples were further sub-divided into
two groups, primary (n = 82) and metastatic (n = 303) in
order to examine the role of DNA methylation in regula-
tion of TKTL1 gene expression within primary and meta-
static melanoma samples. We found positive correlation
of TKTL1 expression with methylation in metastatic sam-
ples (Table 2). These results confirm that DNA hypome-
thylation is associated with aberrant activation of TKTL1
expression in metastatic melanoma.
(See figure on previous page.)
Fig. 1 TKTL1 is highly expressed in human testis and melanoma tumors. a qRT-PCR was employed to measure the expression of TKTL1 in a panel
of normal human tissues and in 38 metastatic melanoma tumor samples. b TKTL1 immunohistochemical staining in testis as positive control and
control IgG staining in tumors as negative control are demonstrated. Representative staining patterns for TKTL1 in metastatic melanoma tumors
are shown. Original magnification, 10 ×. c Graph shows number of TKTL1 positive and negative tumors
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TKTL1 is co-expressed with Cancer Testis Antigens in
melanoma tumors
The epigenetic reactivation of TKTL1 occurs simultan-
eously with DNA hypomethylation of CTAgs in head
and neck cancer [39]. To determine whether TKTL1 ex-
pression in melanoma was linked to the expression of
CTAgs, we queried the TCGA database comprising of
261 melanoma patient samples. We found a significant
tendency toward co-occurrence of many CTAgs with
TKTL1 expression in melanoma tumors (Table 3).
Altered expression of TKTL1 affects the glycolytic
metabolism of melanoma cells
To determine the role of TKTL1 in melanoma, we sought
to manipulate TKTL1 levels in melanoma cell lines by
siRNA-mediated knockdown and vector-mediated over-
expression. Effective suppression of TKTL1 on mRNA
and protein levels in LM-MEL-59 was achieved at 10 nM
concentration of siRNA (Fig. 3a & b). To confirm that the
effects shown by TKTL1 were not off-target effects, we
performed microarray [42] and qRT-PCR for the isoforms
of TKTL1 namely, TKT and TKTL2. We found that TKT
levels were high in both LM-MEL-59 and LM-MEL-44,
















































































Fig. 2 TKTL1 is expressed in metastatic melanoma cell lines and is regulated by promoter hypomethylation. a Using qRT-PCR the expression of
TKTL1 in two melanoma cell lines, LM-MEL-59 and LM-MEL-44 was determined. b TKTL1 expression in LM-MEL-59 and LM-MEL-44 was determined
by IHC. Original magnification, 20×. c Bisulfite conversion and MS-qPCR was performed to assay the promoter methylation status of TKTL1 in
melanocytes and metastatic melanoma cells. Relative levels of methylated and unmethylated products (M/UM) was quantified. d QRT-PCR was
employed to detect changes in expression of TKTL1 by 5-azacytidine treatment in LM-MEL-44 cell line. Values are ± SD of three independent
experiments in triplicate (*, p < 0.05)
Table 1 Integrative analysis of methylation and gene expression




expression (n = 385)
Methylation and exon
expression (n = 385)
Rho P-value Rho P-value
cg09892236 −0.14 0.005 −0.16 0.0024
cg23106779 −0.11 0.04 −0.13 0.01
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testis tissue as a positive control for the expression of
these genes. Upon knockdown with TKTL1 siRNA, TKT
levels were affected by one of the siRNAs but only mod-
estly by the other (Additional file 3: Figure S3).
Transfection with a TKTL1 expression plasmid resulted
in marked overexpression of TKTL1 in LM-MEL-44,
demonstrated by qRT-PCR and immunoblotting (Fig. 3c
& d). No additional bands were detected for TKTL1 as
evident in Additional file 4: Figure S4A&B. High transfec-
tion efficiency was also confirmed with immunofluores-
cence staining (Additional file 4: Figure S4C). Elevated
glucose uptake and lactate production have been detected
during malignant transformation. These metabolic param-
eters of cancer cells are consistent with a pronounced
glycolytic state [43, 44]. To investigate whether TKTL1
expression in melanoma was driving the Warburg effect,
glucose consumption and lactate production were assayed
after TKTL1 interference. Measurements were made on
conditioned medium of LM-MEL-59 cells after treatment
with TKTL1 or control siRNA for 72 h. Depletion of
TKTL1 in these cells caused a substantial decrease in glu-
cose consumption and associated reduction in lactate pro-
duction (Fig. 3e & f) while ectopic expression of TKTL1
in LM-MEL-44 conferred a more glycolytic phenotype
(Fig. 3 g & h). Collectively, these results showed that
TKTL1 enhanced aerobic glycolysis in melanoma.
TKTL1 affects proliferation in melanoma cells
TKTL1 plays an important role in tumor proliferation in
gastric, colon and hepatocellular carcinomas [19, 26, 45].
We investigated whether TKTL1 plays a similar role in
melanoma. TKTL1 knockdown in LM-MEL-59 led to an
increase in the percentage of G0-G1 phase cells and a
decrease in the percentage of S phase cell population
compared to control transfected cells (Fig. 4a, b & e) as
demonstrated by cell cycle analysis. Using MTS assay to
determine total cell number after TKTL1 knockdown,
similar changes were detected. However, effects were
only modest after 48 h (Additional file 5: Figure S5A).
Conversely, TKTL1 overexpression led to a decrease in
the percentage of G0-G1 phase cells in LM-MEL-44 and
an increase in the percentage of S phase cells (Fig. 4c, d
& f). Table 4 depicts the cell cycle phase distributions
under the different conditions. Similarly, MTS assay
demonstrated slightly enhanced proliferation in TKTL1
overexpressing cells compared to empty vector treated
cells, although no significance was achieved (Additional
file 5: Figure S5B). Overall, these results indicate that
TKTL1 levels may affect melanoma cell proliferation.
TKTL1 promotes invasion in melanoma cells
Next, we sought to investigate the effect of TKTL1 on
cell invasion. TKTL1 depleted LM-MEL-59 cells were
significantly less invasive, while TKTL1 overexpressing
LM-MEL-44 cells were more invasive than controls in
the matrigel-coated Boyden chamber assay (Fig. 5a & c).
TKTL1 depleted cells showed 62 % loss and TKTL1
overexpressing cells showed 38 % increase in invasion
(Fig. 5b & d). These results demonstrate a substantive
effect of TKTL1 levels on melanoma cellular invasion.
Oxythiamine does not inhibit proliferation and invasion
in melanoma cells
In tumors expressing high TKTL1, oxythiamine has been
used to block proliferation effectively both in vitro and
in vivo [46]. We treated both LM-MEL-59 and LM-
MEL-44 with the inhibitor in varying dose of 10 and
100 μM (Additional file 6: Figure S6A&B). In both cell
lines no reduction in proliferation was detected. To as-
sess if Oxythiamine induced a G1 phase cell cycle arrest,
LM-MEL-59 cells treated for 72 h with 100 μM of the
inhibitor was subjected to flow cytometric cell cycle ana-
lysis. However, Oxythiamine treatment in our hands
did not cause a G1 phase arrest in melanoma cells
(Additional file 6: Figure S6C). Furthermore, Oxythia-
mine treatment did not alter invasive potential (Additional
file 6: Figure S6D & E).
Table 2 Integrative analysis of methylation and gene expression in primary and metastatic samples (TCGA data analysis)
Probe Id (450 K) Methylation and gene expression Methylation and exon expression
Primary (n = 82) Metastatic (303) Primary (82) Metastatic (303)
Rho P-value Rho P-value Rho P-value Rho P-value
cg09892236 −0.097 0.38 −0.15 0.006 −0.10 0.32 −0.17 0.004
cg23106779 −0.10 0.36 −0.09 0.09 −0.16 0.13 −0.11 0.05
Table 3 Gene expression correlation p value for the co-occurrence
of each gene pair across 261 melanoma patient tumors





Testis-specific serine kinase 6 TSSK6 0.001107
Transcription factor DP family, member 3 TFDP3 0.058881
Sperm autoantigenic protein 17 SPA17 0.061708
Armadillo repeat containing 3 ARMC3 0.061708
Testis expressed 15 TEX15 0.11398
Synovial sarcoma, X breaking point 1 SSX1 0.201966
Centrosomal protein 290 kDa CEP290 0.254303
Synovial sarcoma, X breaking point 5 SSX5 0.280049
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Discussion
Recent studies have shown that TKTL1 plays an import-
ant role in the development and progression of human
tumors [20–26, 29, 47, 48]. In this study, we report that
TKTL1 expression was upregulated in a significant sub-
set of metastatic melanoma tumors and cell lines. In
agreement with other reports, we observed that in-

































































































































































Fig. 3 Ectopic overexpression and knockdown of TKTL1 influences the Warburg effect in melanoma cells. a QRT-PCR was employed to evaluate
the expression of TKTL1 in LM-MEL-59 after treatment with either TKTL1 or control siRNA for 72 h. b Western Blotting with a mouse monoclonal
anti-TKTL1 antibody showed reduction in TKTL1 levels after siRNA treatment in LM-MEL-59 after 72 h. GAPDH was used a loading control. c TKTL1
expression was assessed by qRT-PCR in LM-MEL-44 cells transfected with TKTL1 pcDNA or empty control for 72 h. d Immunoblot of TKTL1
confirmed expression of TKTL1 after transfection of a TKTL1 expression vector in LM-MEL-44. Blots were probed with GAPDH as a control for
loading and transfer. Glucose consumption was measured in cell free supernatant of e LM-MEL-59 cell line following treatment with TKTL1 or
control siRNA for 72 h and g LM-MEL-44 cell line following over-expression of TKTL1 or empty vector control for 72 h. The production of lactate
in culture supernatants was measured in f LM-MEL-59 after knockdown of TKTL1 for 72 h and h LM-MEL-44 after treatment with TKTL1 pcDNA or
empty vector control for 72 h. Values are ± SD of three experiments in triplicate (**, p < 0.005, ***, p < 0.0005)
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Fig. 4 (See legend on next page.)
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and lactate secretion in melanoma cells and this was as-
sociated with changes in the proliferation and invasion
in melanoma cells. Moreover, we could demonstrate that
the TKTL1 promoter is hypomethylated in melanoma
cells compared with melanocytes and consequently
TKTL1 expression could be induced by incubation of
melanoma cells with 5aza. We found a significant associ-
ation of hypomethylation with TKTL1 gene expression
in melanoma patient samples. Additionally, to our
knowledge, this is the first study evaluating the effect of
TKTL1 expression on metabolic and cellular functions
in melanoma.
Abnormal DNA methylation dysregulates gene expres-
sion in cancer and this has been associated with changes
in phenotype and function. In melanoma X-chromosome
coded molecules that can be affected include the CTAg
and TKTL1. Simultaneous reactivation of TKTL1 with
CTAg such as the melanoma antigen family (MAGE-A)
has been reported in lung and head and neck cancers [39].
In melanoma tumors, we have identified that TKTL1 and
CTAgs showed significant correlation in expression. Most
of these CTAgs have been implicated in tumorigenesis
[49–52]. Some of these CTAgs such as Ropporin, TSSK6,
SPA17 and TEX15 have been reported to play important
roles in sperm motility and knockout mice lacking these
genes are often sterile due to profound impairment in
sperm motility [53–56]. CTAgs are repressed by epigen-
etic mechanisms during development and it has been
suggested that the coordinated pathologic reversal of de-
velopmental epigenetic events often occurs in cancer cells
[39]. We speculate that in melanoma aberrant demethyla-
tion occurs as a common underlying mechanism that
links transcriptional activation of TKTL1 and CTAgs that
may cooperate to promote cancer progression by mecha-
nisms such as Warburg effect, motility, proliferation and
apoptosis. Aberrant expression of CTAgs has previously
been associated with poor outcomes in melanoma and
other cancers [34, 36]. It has never been clear why in-
creased expression of these antigens should paradoxically
carry a poorer prognosis. This study may provide the clue,
that increased antigen expression and TKTL1 expression
are both a consequence of a phenotype that results from
methylation changes, and it is this phenotype that associ-
ates pro-tumorigenic metabolic changes with bystander
tumor antigen expression.
Our finding that a subset of metastatic cutaneous mel-
anoma express TKTL1 at the mRNA and protein levels
is consistent with the report of Lange et al., showing that
conjectival melanoma tumors expressed TKTL1 [33].
We also noted elevated levels of TKTL1 in normal testis
tissue, where aerobic glycolysis has been previously de-
tected [57]. Although the Warburg effect appears to be a
wasteful form of metabolism compared to the mitochon-
drial driven oxidative phosphorylation, it is a mechanism
for rapid generation of energy [58].
Heterogeneity within LM-MEL-59 for TKTL1 expres-
sion is representative of most of the tumors that stained
for TKTL1. Ho J et al. reported two distinct populations
of cells that rely on either glycolysis or oxidative phos-
phorylation exist within melanoma tumors and can be
metabolically linked such that lactate from the glycolytic
portion of the tumor helps fuel ATP production through
the oxidative phosphorylation in a process termed
metabolic symbiosis [59]. It is conceivable that TKTL1
positive cells may rely solely on the Warburg effect in
contrast to the TKTL1 negative cells that may rely on
mitochondrial oxidative phosphorylation to support cell
growth. Metabolic symbiosis of TKTL1 positive versus
negative cells warrants further investigation using puri-
fied cell populations.
Recent studies have reported oxidative respiration
plays an important role in melanoma metabolism in
addition to glycolysis in vitro [14, 59, 60]. Activating mu-
tations in the BRAF protein kinase are the most com-
mon genetic alterations in melanoma, found in around
40 % of tumors. Many studies have shown a role for BRAF
signalling in the regulation of melanomas metabolism
(See figure on previous page.)
Fig. 4 Loss of TKTL1 expression changes cell cycle distribution of melanoma cells. Cell cycle phases were determined by propidium iodide
staining of melanoma cells and subsequent flow cytometric analysis. A representative histogram of cell cycle analysis of LM-MEL-59 is shown after
a control siRNA treatment and b TKTL1 siRNA treatment. Analysis of percentage of cells in e G0-G1 phase and S phase cell after treatment of
LM-MEL-59 with TKTL1 or control siRNA. Values are ± SD of three experiments in triplicate (*, p < 0.05, **, p < 0.005). Histograms depicting distribution of
cell cycle phase in LM-MEL-44 after treatment with c empty vector control and d TKTL1 pcDNA. Cell cycle distribution of f GO-G1 and S phase cell
population after 48 h of ectopic expression of TKTL1 or empty vector in LM-MEL-44 was performed. Values are ± SD of three experiments in triplicate
(*, p < 0.05, **, p < 0.005)
Table 4 Comparison of cell cycle distribution after TKTL1
knockdown and overexpression
Treatment (LM-MEL-59) Sub G1 (%) G0-G1 (%) S (%) G2-M (%)
Control siRNA 8.27 48.26 38.84 12.89
TKTL1 siRNA 7.9 58.17 30.71 11.11
p Value 0.78 0.004 0.01 0.65
Treatment (LM-MEL-44) Sub G1 (%) G0-G1 (%) S (%) G2-M (%)
Empty vector control 18.05 79.55 17.39 3.05
TKTL1 pcDNA 8.89 65.55 31.42 3.05
p Value 0.02 0.001 0.01 0.99
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[8, 61, 62]. Melanomas treated with agents that target
oncogenic BRAF undergo a reversal of the Warburg
effect and become dependent on oxidative phosphor-
ylation [61, 62]. However, both cell lines used to investi-
gate the role of TKTL1 in this study lack the activating
mutations in BRAF, so BRAF mutations do not appear to
be a prerequisite for TKTL1-driven aerobic glycolysis.
This is consistent with TKTL1 being activated through an
epigenetic mechanism that is independent of BRAF muta-
tional status. A glycolytic profile of melanoma cell lines
has recently been identified by metabolic profiling and the
study reported that melanoma cells were inherently more
glycolytic than melanocytes and could adapt their meta-
bolic program to environmental challenges and also found
that all melanoma cells evaluated maintained functional
mitochondria [14]. This does not invalidate a role for the
Warburg effect, and suggests that metabolic flexibility
may occur, enabling a survival advantage for tumors grow-
ing in diverse environments. The mechanisms that tip the
balance towards more glycolysis and less respiration in tu-
mors are emerging.
In circumstances where glucose metabolism exceeds
the capacity of a cell to assimilate or store glucose-
derived carbon, cells with high levels of TKTL1 expres-
sion have a growth advantage when compared to those
with low levels of TKTL1. A correlation between glucose
uptake and proliferation has been demonstrated in sev-
eral cell lines, for instance in ovarian adenocarcinoma
and breast cancer cells [63, 64]. Our finding that TKTL1
expression enhances proliferation is consistent with these
findings. The important question is whether this reflects a
dependence on TKTL1 as a mechanism for tumor pro-
gression or survival. If so, it may be a useful therapeutic
target, in those cases where it is overexpressed.
Langbein et al. examined 70 colon cancers and found
increased TKTL1 protein levels in invasive tumors com-
pared to non-invasive tumors and healthy tissue [17].
High levels of TKTL1 were also correlated with invasion
and poor prognosis in urothelial, laryngeal squamous
and colorectal cancer [17, 29]. Our observation that
TKTL1 promotes invasiveness in vitro indicates that the
metabolic pathways that support tumor progression are
likely to be complex. Cells with increased TKTL1 showed
increased rate of glycolysis with production of high levels
of lactate. Cancer cells in general seem to adapt to the
acidic conditions better than surrounding cells and this
may promote the degradation of host matrix leading to
greater invasiveness and thereby contributing to metasta-
ses. Furthermore, the acidic microenvironment can en-
hance survival of cancer cells by inhibiting anti-cancer
immune responses [65, 66]. Thus, the TKTL1-driven
metabolic adaptation may promote cancer progression
through a variety of mechanisms.
Although our results suggest that TKTL1 could be a
therapeutic target in melanoma, treatment with oxythia-
mine, a thiamine antagonist, was ineffective even though
it was previously shown to decrease proliferation in tu-
mors with high TKTL1 expression [46]. Similarly, earlier
studies demonstrated that oxythiamine was not effective
in most thyroid cancer cells expressing high TKTL1 and




























































Empty vector TKTL1 pcDNA
Fig. 5 TKTL1 enhances invasive behaviour in melanoma. Melanoma
cells were plated out and transfected with either 10nM control
siRNA or TKTL1 specific siRNA and subjected to invasion assay.
a Representative images of invasion of LM-MEL-59 is shown (scale
bar = 100 μm). b The graph shows the total number of invasive cells
counted. c Invasiveness of melanoma cells LM-MEL-44 after treatment
with empty vector control or TKTL1 pcDNA was tested, images
captured (scale bar = 100 μm) and d invasion was quantified as above.
Values are mean ± SD of three independent experiments in triplicate
(*p < 0.05, **p < 0.005)
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in vivo in normal rat tissues that expressed high TKTL1
[30, 67]. Using computer modelling, 38 amino acid dele-
tion was introduced into the normal human TKT gene
to obtain a variant analogous to TKTL1. However, this
variant lacked catalytic activity exhibited by the TKT
protein, and Meshalkina et al. therefore suggest that
TKTL1 is distinct from the thiamine diphosphate de-
pendent enzyme TKT [68]. Our data suggests that we
cannot rule out the possibility that TKT acts in concert
with TKTL1 as we observed that TKT is highly ex-
pressed in melanoma cell lines and knockdown of TKTL1
impacts TKT expression, if only modestly. However, given
the fact that the overexpression of TKTL1 in LM-MEL-44
showed opposing effects, and that one of the siRNAs is
not changing TKT levels significantly while having the
same functional effects in LM-MEL-59, TKTL1 is clearly
the main player in the observed effects. Recently, more
specific inhibitors of transketolases have been developed
[69]. Further studies will determine whether these are
more effective on TKTL1-expressing cancers.
Conclusion
The functional significance of the increased TKTL1 in
melanoma, its association with DNA hypomethylation
and the Warburg effect has not previously been reported.
Here, we demonstrate that melanoma cells expressing
TKTL1 are predominately glycolytic and that TKTL1 ex-
pression increases both cellular proliferation and invasion.
Melanoma cells exhibit metabolic plasticity and compen-
satory mechanisms that allow metabolic adaptations have
previously made it difficult to exploit metabolic targets for
therapy. Here we show that a methylation defect likely
leads to TKTL1 over expression. We postulate that this
overexpression allows survival within the hypoxic tumor
micro-environment and selects for cells that bear it.
Consequently their dependence on glycolysis may arise
through a mechanism that does not reflect metabolic plas-
ticity. This in turn points to the potential of targeting
TKTL1-expressing melanomas particularly if they prove
to be dependent on it for their survival. Ultimately the
success of such a strategy will depend on this and on the
quality of any drugs that are developed. Further investiga-
tions will determine the extent of which is useful target
for therapeutic intervention in metastatic melanoma.
Methods
Cell culture and archival patient materials
Melanoma cell lines were established from resected mel-
anoma metastases by mechanical dissociation of tissue
with subsequent overnight digestion in media containing
collagenase IV and DNAse at 37 °C. Established cell
lines were Mycoplasma-tested using the MycoAlert test
(Lonza Rockland, Inc.) and STR-profiled for identity
confirmation.
Following pathological examination post-surgery tumour
fragments were formalin-fixed and paraffin-embedded
(FFPE) by staff at the Austin Health Tissue Bank. All mel-
anoma tissue was derived from metastases resected from
regions distant to the primary tumor; no locoregional me-
tastases or primary tumors were included. Tissue micro-
array consists of tumor tissue embedded in a block and
allows analysis of multiple patient tissue samples on the
same slide. The study cohort consisted of 81 patients with
stage III and IV metastatic melanoma. All tissue donors
provided written informed consent for tissue collection
and research, which was covered by protocols approved
by the Austin Health Human Research Ethics Committee,
Melbourne, Australia (approval number H2012/04446). All
cell lines were matched with their donors by HLA-typing.
Cells were cultured in RPMI1640 supplemented with 10 %
fetal calf serum (FCS) as described previously [42].
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA was extracted using the RNEasy mini kit
(Qiagen). We have performed on column DNAase diges-
tion using RNase-Free DNase at room temperature (20–
30 °C) for 15 min in accordance to Qiagen RNEasy Kit
instructions. Spectrophotometric quantification using
Nanodrop confirmed purity of RNA and absence of
DNA in our samples. In addition to this to prevent any
interference by residual DNA contamination, we have
performed qRT-PCR with primers that are intron span-
ning such that genomic DNA will not be amplified.
RNA was reverse transcribed using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
Following reverse transcription, qRT-PCR was per-
formed using the SensiFAST SYBR Lo-ROX kit (Bioline),
and a Vii-A7 thermocycler (Applied Biosystems). The
primers for TKTL1 and β-actin (internal control) were
synthesized by Sigma Aldrich and the sequences were as
follows: TKTL1 primer (forward) 5’-CCA CCT GAT
TAC AGA GTT GGT G-3’ and (reverse) 5’-CTC TGT
TGT TCG CGT AGC C-3'; β-actin (forward) 5'-CCA
ACC GCG AGA AGA TGA-3’ and (reverse) 5'-CCA
GAG GCG TAC AGG GAT AG-3’, TKT primer (forward)
5’-TGT GTC CAG TGC AGT AGT GG-3’ and (reverse)
5’-ACA CTT CAT ACC CGC CCT AG-3’; TKTL2 primer
(forward) 5’-ACG ACC GGT TCA TCC TCT C-3’ and
(reverse) 5’-TCC ACC CAA GCA GCATAG A-3’.
Immunohistochemistry
Immunohistochemistry was performed on tissue microar-
rays constructed from formalin-fixed paraffin-embedded
(FFPE) metastatic melanomas and melanoma cell lines
after citrate buffer (pH 6.0) antigen retrieval for 30 min
using the Dako Envision+ kit (Dako). Incubation with 1×
protein blocking buffer for one hour at room temperature
was followed by overnight incubation at 4 °C with mouse
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monoclonal anti-TKTL1 antibody (clone JFC12T10; 1:200
dilution) previously described by Langbein et al. [17].
60 min incubation with secondary anti-mouse antibody
HRP (Dako) was performed. 3-amino-9-ethylcarbazole
(AEC) was used as chromagen (Vector Laboratories).
Slides were counterstained with hematoxylin, images were
captured and immunohistochemical reactivity was evalu-
ated by two independent investigators. Patient tumor
cores were scored TKTL positive based on cytosolic stain-
ing in minimum of 10 % tumor cells. Human testis tissue
was used as the positive control for TKTL1 and a negative
control, for which the primary antibody was substituted
with the same concentration of mouse IgG.
Bisulfite treatment of DNA and quantitative methylation-
specific PCR (MS-qPCR)
Genomic DNA was extracted using phenol chloroform
(Qiagen), and bisulfite modification of genomic DNA
was performed according to the manufacturer’s instruc-
tions (Qiagen). Methylation specific and methylation inde-
pendent primers (Sigma Aldrich) were used to quantify
the relative levels of methylated and unmethylated prod-
ucts within PCR amplified samples. The primers are as
follows: TKTL1 methylated primer (forward) 5'-GAC
GTC TAA AAA ACG AAT AAC GC-3' and (reverse) 5'-
AAA GAA CAT TTT GTA TTC GCG C -3'; TKTL1
unmethylated primer (forward) 5'-CAA CAT CTA AAA
AAC AAA TAA CAC C-3' and (reverse) 5'-GAA AGA
AGA TTT TGT ATT TGT GTG G-3'; β-actin primer
(forward) 5'-TGG TGA TGG AGG AGG TTT AGT AAG
T -3' and (reverse) 5'-AAC CAA TAA AAC CTA CTC
CTC CCT TAA -3'.
Data set analysis
We acquired data form The Cancer Genome Atlas
(TCGA) data portal (www.cbioportal.org). We started
our analysis with the Level 3 data download (normalized
data) of Illumina Infinium Human Methylation 450 k
BeadChip array (450 k array) (http://www.illumina.com/
products/methylation_450_beadchip_kits.html), and Illu-
mina Hiseq RNA-Seq Platforms with RNA-seq gene and
RNA-seq exon expression datasets (http://www.illumina.
com/applications/sequencing/rna.html) of melanoma from
the TCGA website (https://tcga-data.nci.nih.gov/tcga/data
AccessMatrix.htm?mode=ApplyFilter&showMatrix=true&
diseaseType=SKCM&tumorNormal=TN&tumorNormal=
T&tumorNormal=NT). Methylation measurement of
each CpG probe was called β and was calculated as the
methylated signal divided by the sum of the methylated
and the unmethylated signal. Two methylation probes in
accordance with Illumina annotation and UCSC genome
browser that overlapped with our targeted region by MS-
QPCR were selected. As there were some CpG sites be-
tween the two probes that was not covered by 450 k
platform, we only investigated the correlation between
these two probes in the 450 k platform by Spearman cor-
relation coefficients statistical test (p < 0.05) to estimate
methylation level of our targeted region. Subsequently,
correlations between the two probes were separately
assessed with TKTL1 gene expression and exon expres-
sion. All analysis was performed by R statistical program-
ming language (3.1.1).
5-aza-2′-deoxycytidine (5aza) treatment
Melanoma cell line LM-MEL-44 was treated with
0.1 μM of 5aza (Sigma) for 4 days. The medium and the
5aza were refreshed on alternate days. Cells were conflu-
ent at time of harvest.
TKTL1 overexpression construct and RNA interference
transfection
The plasmid encoding TKTL1 (clone ID 4825931) was ob-
tained from Life Technologies and the TKTL1 gene was
subcloned into pcDNA3.1(+) vector (Promega). Cells were
transfected using Lipofectamine 2000 (Life Technologies).
Empty vector control used was pcDNA3.1(+). For transi-
ent siRNA transfection, cells at 30 % confluence were
transfected using a control siRNA and two different Silen-
cer select siRNAs targeting TKTL1 (s224894 and s15774)
at 10nM final concentration (Ambion) with Lipofectamine
RNAiMAX according to the manufacturer’s protocol
(Invitrogen).
Immunoblot analysis
Cells were lysed in RIPA buffer (Sigma) and protein con-
centration quantified using the BCA protein assay (Thermo
Scientific). Samples were separated using NuPAGE 4–10 %
BisTris gels (Life Technologies) and MES [2-(N-morpho-
lino) ethanesulfonic acid] SDS running buffer (Life Tech-
nologies). Transfer to PVDF membrane (Milipore) used a
semi-dry transferblot (Bio-Rad Laboratories). Blocking
was performed with Odyssey blocking buffer (Millenium
Science), followed by incubation with anti-TKTL1 anti-
body (mouse monoclonal antibody, clone JFC12T10,
1:100) or anti-GAPDH antibody 1:1000 (Cell Signalling)
overnight at 4 °C, and IRDye 680/800 secondary goat anti-
mouse and anti-rabbit antibodies (Millenium Science)
were incubated for one hour at room temperature. Images
were acquired using Odyssey infrared imaging system
(LI-COR Biosciences).
Immunofluorescence
LM-MEL-44 transfected with TKTL1 overexpression plas-
mid construct was incubated for 72 h and then fixed with
4 % paraformaldehyde, stained with anti-TKTL1 rabbit
polyclonal antibody (ab87187, Abcam) which was applied
at 3 μg/mL concentration overnight at 4 °C and with Alexa
flour 555 (anti-rabbit) conjugated secondary antibody for
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45 min at room temperature (Molecular probes, USA).
Cells were counter stained with DAPI for 10 min.
Measurement of extracellular glucose and lactate
Cell-free supernatant of cultured melanoma cells was
collected, and glucose and lactate concentrations were
determined using colorimetric glucose and lactate assay
kits (Biopharma). The assays were performed according
to the manufacturer’s instructions and absorbance was
measured at 340 nm.
Cytofluorometric analysis
Cell viability and cell cycle analysis was assessed after
staining with propidium iodide. TKTL1 was over-
expressed or depleted in melanoma cells for 48 h. Cells
were stained with 200 μl propidium iodide solution con-
sisting of 50 μg/ml propidium iodide, 0.1 mg/ml RNAse
A and 0.05 % Triton-X (all Sigma) in PBS. Cells were in-
cubated overnight at 4 °C and analyzed by flow cytome-
try using the FL2 channel.
Proliferation assay
MTS colorimetric assay was performed using standard
protocols. Twenty thousand cells were seeded per well of
a 96 well plate and treated as indicated. Relative cell num-
bers were measured using the CellTiter 96® AQueous One
Solution Cell Proliferation Assay (Promega Corporation).
Invasion assay
Invasion assays were performed with Boyden chamber in-
sert (6.5 mm diameter inserts with 8.0 μm pores) coated
with Matrigel (Becton, Dickinson and Company) as de-
scribed previously [70]. Briefly, melanoma cells were
seeded at 40,000 cells per insert. 600 μl of media contain-
ing 10 % FCS was added as chemo attractant to the lower
compartment. The cells were incubated overnight at 37 °C
and subsequently fixed with 4 % paraformaldehyde,
stained with 0.1 % Crystal Violet and cells on the upper
surface of the insert were removed. Invaded cells on the
bottom side were counted from three random fields of
view observed with a 10X objective lens. Average of in-
vaded cells across three fields of view was calculated from
independent experiments repeated three times.
Oxythiamine treatment
Melanoma cells were treated with varying dose of oxy-
thiamine (Sigma) as indicated for 24, 48 and 72 h. Fol-
lowing treatment cells were subjected to proliferation,
invasion and cytofluorometric analyses.
Statistical analysis
All statistical comparisons of data sets were performed
using Student’s two-tailed t-test in Prism software version
5.00 (GraphPad Software Inc). Statistical significance was
set at p <0.05.
Additional files
Additional file 1: Figure S1. TKTL1 is expressed in a subset of
melanoma tumours and melanoma cell lines. (A) Representative staining
patterns for TKTL1 in metastatic melanoma tumors are shown. Arrows
indicate nuclear staining for Melanin. Original magnification, 200 μm.
(B) QRT-PCR for expression level of TKTL1 in a panel of 53 metastatic
melanoma cell lines. (C) High magnification staining pattern of TKTL1 in
melanoma cell line LM-MEL-59. Arrows indicate nuclear staining for
Melanin. Original magnification, 200 μm. (PPTX 1827 kb)
Additional file 2: Figure S2. Correlation of TKTL1 gene expression with
DNA methylation in melanoma patients. Exon expression data was
compared to methylation patterns of TKTL1 and Spearman correlation
coefficients were calculated. Methylation status at the CpG site (A)
cg09892236 and (B) cg23106779 was inversely correlated with TKTL1
gene expression in melanoma samples. (PPTX 114 kb)
Additional file 3: Figure S3. TKT and TKTL2 expression in melanoma cells.
(A) TKT, (B) TKTL1 and (C) TKTL2 expression in LM-MEL-59 after treatment with
two TKTL1 siRNAs or control siRNA for 72 h. Testis tissue was used as positive
control for the expression of TKT, TKTL1 and TKTL2. (PPTX 69 kb)
Additional file 4: Figure S4. TKTL1 expression in melanoma cells after
gain and loss of function experiments. (A) Western Blotting with the
mouse monoclonal anti-TKTL1 antibody showed reduction in TKTL1 levels
after siRNA treatment in LM-MEL-59 after 72 h. GAPDH was used a
loading control. (B) Western Blotting of TKTL1 confirmed expression of
TKTL1 after transfection of a TKTL1 expression vector in LM-MEL-44. Blots
were probed with GAPDH as a control for loading and transfer.
(C) Immunofluorescence confirmed increase in TKTL1 localization in
LM-MEL-44 after transfection with TKTL1 expression vector. In contrast no
TKTL1 was detected in LM-MEL-44 transfected with empty control vector.
Scale bar =100 μm). (PPTX 590 kb)
Additional file 5: Figure S5. TKTL1 expression in melanoma affects
proliferation of cells. (A) Measurement of absorbance of LM-MEL-59 cells
after TKTL1 siRNA or control siRNA treatment for 48 h by performing MTS
assay. (B) Measurement of absorbance of LM-MEL-44 cells after
overexpression of TKTL1 or empty vector for 48 h. (PPTX 57 kb)
Additional file 6: Figure S6. Oxythiamine treatment in melanoma cells.
Measurement of absorbance of (A) LM-MEL-59 or (B) LM-MEL-44 cells
after treatment with 10 μM, 100 μM Oxythiamine or control media for 24,
48 and 72 h by performing MTS assay. (C) Cell cycle phases were determined
by propidium iodide staining of LM-MEL-59 cells and subsequent flow
cytometric analysis of percentage of cells in subG0, G0-G1, S and G2-M
phases after treatment of LM-MEL-59 with 100 μM Oxythiamine or control
media. Values are ± SD of three experiments. (D) Representative images of
invasion of LM-MEL-59 is shown after treatment with 100 μM Oxythiamine
(scale bar = 50 μm) and (E) invasion was quantified. (PPTX 183 kb)
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